URGENT. We could lose access.
Protect ADHD Prescription Medication. ACT NOW!
Now more than ever, your voice matters. Together, we can raise awareness, influence policy, and drive meaningful, lasting change for our ADHD community.
In less than 2 minutes, you can make your voice heard.
The MAHA Commission plans to release policies on August 12 that could restrict access to FDA-approved ADHD medications by questioning ADHD diagnoses and the safety of stimulant treatments, despite decades of research showing their effectiveness and safety. These medications are a key part of evidence-based ADHD care, which, if left untreated, can lead to serious health risks, shorter lifespans, and high societal costs ($143–$266 billion annually).
Advocacy group CHADD warns that the MAHA Report contains scientific inaccuracies and omissions that risk spreading stigma and misinformation. They urge people to contact their US Senators and Representatives to:
Defend access to FDA-approved ADHD medications
Reject limits on evidence-based treatment
Maintain funding for ADHD research and insurance coverage
The call to action stresses the need for policies guided by science to protect public health and the ADHD community.
ACT NOW
Do we really want to go back to a time when ADHD was simply beaten out of us? Be the person you needed when you were a child. Please help.
